MedPath

Guideline-Informed Treatment-Personality Disorders Youth: Exploring the feasibility of a generic early intervention program for emerging personality disorder in adolescents

Conditions
personality pathology
10034726
Registration Number
NL-OMON51286
Lead Sponsor
Psychotherapeutisch Centrum De Viersprong (Halsteren)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
75
Inclusion Criteria

The targeted participants are adolescents with emerging symptoms of personality
pathology. Only participants between the ages of 12 and 18 years will be
included in the study. Participants for the study will be recruited after a
thorough screening for eligibility (see below). More specifically, participants
will be considered as eligible for the study when they meet the threshold for
personality disorders according to the alternative model for personality
disorders in DSM-5, meaning they should display moderate or more severe
impairments in personality functioning (score >= 2,) as assessed through the
Semi-structured Interview for Personality Functioning DSM-5 (STiP-5.1).

Exclusion Criteria

Exclusion criteria are: insufficient mastery of the Dutch language, severe risk
of suicide requiring immediate intervention and cognitive impairment (IQ <75).
The WAIS-IV will be administered when intellectual impairment is suspected.
Patients will also be excluded when they meet the DSM-5 criteria for (severe)
psychotic disorders, autism spectrum disorder and (severe) substance abuse.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary outcome is the severity of PD symptoms.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>secondary outcomes are level of personality, social and academic functioning,<br /><br>severity of depressive- and anxiety symptoms, emotion dysregulation symptoms<br /><br>and the severity of suicidal ideation and behaviour. </p><br>
© Copyright 2025. All Rights Reserved by MedPath